- 专利标题: DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases
-
申请号: US16695653申请日: 2019-11-26
-
公开(公告)号: US20200093831A1公开(公告)日: 2020-03-26
- 发明人: John Gerard Geisler , Robert Alonso , Peter Anthony Crooks , Narsimha Reddy Penthala , Zaineb Albayati
- 申请人: MITOCHON PHARMACEUTICALS, INC. , BIOVENTURES, LLC
- 申请人地址: US PA Radnor US AR Little Rock
- 专利权人: MITOCHON PHARMACEUTICALS, INC.,BIOVENTURES, LLC
- 当前专利权人: MITOCHON PHARMACEUTICALS, INC.,BIOVENTURES, LLC
- 当前专利权人地址: US PA Radnor US AR Little Rock
- 主分类号: A61K31/5375
- IPC分类号: A61K31/5375 ; C07C229/22 ; C07C229/08 ; A61K31/4402 ; A61K31/44 ; C07C229/26 ; C07C271/52 ; C07C219/04 ; C07C271/44 ; A61K31/221 ; C07F9/09 ; A61K31/661 ; A61K31/4406 ; A61K31/223 ; C07C205/37 ; A61K31/27 ; A61K31/265 ; A61K31/40 ; C07F9/12 ; C07C323/58 ; A61K31/4409 ; A61K31/06 ; A61K31/495 ; A61K31/4453
摘要:
A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.